Experience

Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A/Regulation S offering of $750 million aggregate principal amount of 3.250% notes due 2023 and $650 million aggregate…

Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $20 billion in aggregate principal amount of senior notes by Halfmoon Parent,…

Davis Polk advised Zai Lab Limited in connection with its first follow-on offering of $150 million of American Depositary Shares representing 7,500,000 ordinary shares of the company. The…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Illumina, Inc. of $750 million aggregate principal amount of its 0.0%…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $300 million aggregate principal amount of its floating-rate senior notes…

Davis Polk advised ViewRay, Inc. in connection with its $172.5 million SEC-registered follow-on offering of 18,648,649 shares of common stock, which included the full exercise of the…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the approximately $125 million public offering of common stock of…

Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…

Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the Hong Kong Stock Exchange. The gross proceeds from the offering…

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with separate private exchange offers for its existing 12% senior secured notes due 2020 held by certain holders for new…